View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
May 22, 2020

Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets

By Victoria Smith

Anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatments being developed for Covid-19 are expected to have better therapeutic effects than cytokine-specific therapies such as interleukin (IL)-6 and IL-1 inhibitors.

These antibodies target an earlier point in the inflammation pathway than inhibitors that target cytokines like IL-6 and IL-1. Therefore, they could have a broader and better therapeutic response. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena